New eye drop aims to lower pressure in glaucoma patients
NCT ID NCT07335211
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new eye drop called HUC3-637 in 206 adults with primary open-angle glaucoma or ocular hypertension. The goal is to see if it safely lowers eye pressure better than an existing active control. Participants will use the drops daily and have their eye pressure measured over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HUC3-637 eye drops
- What this could lead to
- If successful, this could provide a new, effective eye drop option to help control eye pressure in people with glaucoma or high eye pressure.
- What could go wrong
- This is a Phase 3 trial, but results may not confirm superiority over existing treatments. Some patients may not respond or may experience side effects like eye irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kangbuk Samsung Hospital
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which laser best tames glaucoma pressure?
- Could a daily reading drill restore lost reading skills in glaucoma?
- Could a single eye implant replace years of glaucoma drops?
- Which eye implant best tames glaucoma? a head-to-head trial aims to find out.
- One drop before the laser: could this simple step save your sight?
- New surgical tool aims to lower eye pressure in glaucoma patients